Investigational dementia therapies include targeting APOE directly, such as reducing APOE4 expression, with antibodies (Xiong et al., 2021), anti-sense oligonucleotides (Huynh et al., 2017), gene therapy, and gene editing (Liu et al., 2013; Yamazaki et al., 2016). The gene discussed is APOE; the disease is dementia.